Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies.
Tlemsani C, Takahashi N, Pongor L, Rajapakse VN, Tyagi M, Wen X, Fasaye GA, Schmidt KT, Desai P, Kim C, Rajan A, Swift S, Sciuto L, Vilimas R, Webb S, Nichols S, Figg WD, Pommier Y, Calzone K, Steinberg SM, Wei JS, Guha U, Turner CE, Khan J, Thomas A. Tlemsani C, et al. Among authors: schmidt kt. Sci Transl Med. 2021 Jan 27;13(578):eabc7488. doi: 10.1126/scitranslmed.abc7488. Sci Transl Med. 2021. PMID: 33504652 Free PMC article.
Reviewing the role of healthy volunteer studies in drug development.
Karakunnel JJ, Bui N, Palaniappan L, Schmidt KT, Mahaffey KW, Morrison B, Figg WD, Kummar S. Karakunnel JJ, et al. Among authors: schmidt kt. J Transl Med. 2018 Dec 4;16(1):336. doi: 10.1186/s12967-018-1710-5. J Transl Med. 2018. PMID: 30509294 Free PMC article. Review.
Insulin potentiation therapy for cancer?
Sissung TM, Schmidt KT, Figg WD. Sissung TM, et al. Among authors: schmidt kt. Lancet Oncol. 2019 Feb;20(2):191-192. doi: 10.1016/S1470-2045(19)30003-8. Lancet Oncol. 2019. PMID: 30712796 No abstract available.
A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer.
Peer CJ, Schmidt KT, Kindrick JD, Eisner JR, Brown VV, Baskin-Bey E, Madan R, Figg WD. Peer CJ, et al. Among authors: schmidt kt. Cancer Chemother Pharmacol. 2019 Oct;84(4):759-770. doi: 10.1007/s00280-019-03908-0. Epub 2019 Jul 31. Cancer Chemother Pharmacol. 2019. PMID: 31367790 Free PMC article.
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment.
Madan RA, Schmidt KT, Karzai F, Peer CJ, Cordes LM, Chau CH, Steinberg SM, Owens H, Eisner J, Moore WR, Dahut WL, Gulley JL, Figg WD. Madan RA, et al. Among authors: schmidt kt. Clin Genitourin Cancer. 2020 Aug;18(4):258-267.e1. doi: 10.1016/j.clgc.2019.11.002. Epub 2020 Mar 29. Clin Genitourin Cancer. 2020. PMID: 32327394 Free PMC article. Clinical Trial.
80 results